Eli Lilly's tirzepatide cut the risk of developing type 2 diabetes for people with pre-diabetes by 94%, according to new ...

The agency’s new guidelines are created to eliminate pharmaceutical company practices that minimize or distract consumers ...

Investors continued to see multiple shades of light red as biotechs continued to struggle in the wake of the postelection ...

A key regulatory committee sided against the drug this summer. But an appeal from Eisai appears to have worked, teeing ...

Three games into its new campaign, Indiana women’s basketball has an identity crisis.

Shares of Hims & Hers slid after Amazon.com said it would offer cheap treatments for concerns like hair loss, skin care and ...

And Kentucky has been very good for Independence (6-3), which was slated to host James Monroe in the first round of the Class ...

Attorneys for the school district say that the legal action is in part due to self-funded insurance plans that has possibly ...

INDIANAPOLIS — Indiana women’s basketball’s loss to Butler University unfolded with a story all too familiar to the Hoosiers’ ...

Hims & Hers Health Inc. shares tumbled 22% Thursday, on concerns that Amazon.com Inc.'s latest push into healthcare will disrupt Hims & Hers' business.

A European regulatory committee now recommends approval of the Alzheimer’s treatment lecanemab a few months after rejecting ...